EXHIBIT 10.13 DEVELOPMENT, LICENSE AND MARKETING AGREEMENT BY AND BETWEENDevelopment, License and Marketing Agreement • September 4th, 1998 • Centaur Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIRD AMENDMENT TO DEVELOPMENT, LICENSE AND MARKETING AGREEMENTDevelopment, License and Marketing Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Third Amendment (the “Amendment”) to the Development, License and Marketing Agreement dated June 26, 1995, as amended, by and between Centaur Pharmaceuticals, Inc. and Astra AB (the “License Agreement”) is made this 18th day of June, 2002 by and between Centaur Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1220 Memorex Drive, Santa Clara CA 95050-2812 (“Centaur”) and AstraZeneca AB, successor to Astra AB, a corporation organized and existing under the laws of Sweden, S-151 85 Sodertalje, Sweden (“AstraZeneca”). Unless otherwise provided, all capitalized terms herein shall have the meaning as set forth in the License Agreement, including any exhibits or amendments thereto.
AMENDMENT TO DEVELOPMENT, LICENSE AND MARKETING AGREEMENT ENTERED INTO AS OF JUNE 26, 1995, AND MADE BY AND BETWEEN ASTRA AB AND CENTAUR PHARMACEUTICALS, INC.Development, License and Marketing Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Amendment, entered into July 8, 1997, is made by1 and between Astra AB, a corporation organized and existing under the laws of Sweden, S-151 85 Sodertalje, Sweden (“Astra”) and Centaur Pharmaceuticals, Inc. a corporation organized and existing under the laws of the State of Delaware, 484 Oakmead Parkway, Sunnyvale, CA 94086, USA (“Centaur”).
Development, License and Marketing Agreement By and Among Jagotec AG, SkyePharma PLC (in connection with parent guaranty only), Kos Life Sciences, Inc. and Kos Pharmaceuticals, Inc. (in connection with parent guaranty only) Dated As Of May 5, 2006Development, License and Marketing Agreement • September 14th, 2006 • Kos Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Development, License and Marketing Agreement, made as of May 5, 2006 (the “Effective Date”), is by and between Kos Life Sciences, Inc., a company organized and existing under the laws of Delaware, having a place of business located at 2200 N. Commerce Parkway, Weston, FL 33326 (“Kos”), and solely with respect to Section 15.21.1 Kos Pharmaceuticals, Inc., a corporation organized and existing under the laws of Florida, having offices located at 1 Cedar Brook Drive, Cranbury, NJ 08512 (“Kos Pharmaceuticals”), Jagotec AG, a corporation organized and existing under the laws of Switzerland, having offices located at Eptingerstrasse 51, CH—4132 Muttenz, Switzerland (“Jagotec”) and solely with respect to Section 15.21.2, SkyePharma PLC, a company registered in England and Wales, having offices located at 105 Piccadilly, London W1J 7NJ, United Kingdom (“SkyePharma”).
AMENDMENT TO DEVELOPMENT, LICENSE AND MARKETING AGREEMENT ENTERED INTO AS OF JUNE 26, 1995, AND MADE BY AND BETWEEN ASTRA AB AND CENTAUR PHARMACEUTICALS, INC. This Amendment, entered into July 8, 1997, is made by /1/ and between Astra AB, a...Development, License and Marketing Agreement • July 15th, 1998 • Centaur Pharmaceuticals Inc • Pharmaceutical preparations
DEVELOPMENT, LICENSE AND MARKETING AGREEMENT BY AND BETWEEN ASTRA AB AND CENTAUR PHARMACEUTICALS, INC. DATED JUNE 26, 1995Development, License and Marketing Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations • New York
This Development, License and Marketing Agreement (the “LICENSE AGREEMENT”), entered into as of June 26, 1995 (the “EFFECTIVE DATE”), is made by and between
